PR Newswire
HOLON, Israel, July 24, 2017
HOLON, Israel, July 24, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company, announced
today that the Company will release its second quarter financial results on Wednesday, August 2,
2017 before the U.S. financial markets open. Management will host a live webcast to review the results and provide a
corporate update at 10:00 AM ET.
To access the live conference call by telephone, please dial 1-888-668-9141 from the US, or +972-3-918-0609 internationally.
The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on
the Company's website.
About Compugen
Compugen is a leading therapeutic discovery company whose mission is to utilize its broadly applicable predictive discovery
infrastructure to discover novel drug targets and develop first-in-class therapeutics. Our current pipeline consists of early and
preclinical stage immuno-oncology programs based on novel drug targets discovered internally, primarily immune checkpoint and
myeloid protein target candidates. These programs focus on the development of first-in-class cancer immunotherapy drugs with the
potential to harness the immune system to provide treatment solutions in areas of unmet medical need in various cancer types and
patient populations, both as monotherapy and in combination with other drugs. In addition, our pipeline currently includes a
preclinical fusion protein autoimmune product candidate. Compugen's business model is based on selectively entering into
collaborations for its novel target candidates and related drug product candidates at various stages of research and development
under revenue-sharing agreements. The Company is headquartered in Israel, with R&D
facilities in Israel and South San Francisco. At the US facilities, therapeutic monoclonal
antibodies are discovered and developed against the Company's novel drug target candidates. For additional information, please
visit Compugen's corporate website at http://www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
SOURCE Compugen Ltd.